BXT-110 / BrainXell - LARVOL DELTA

BrainXell Showcases Pioneering iPSC Research and Promising In Vivo Data for BXT-110 for Parkinson's Disease at the 2025 Society for Neuroscience Annual Meeting (PRNewswire) - "The data demonstrates more than 75 percent FOXA2+/OTX2+ expression, over 60% TH+ neurons in vitro and greater than 60 percent graft survival in vivo. Functional efficacy in rodent model, demonstrated by a significant behavioral recovery within 12 weeks post transplantation with BXT-110, supporting BXT-110 as a robust candidate for disease-modifying therapy."

Preclinical • Parkinson's Disease

BrainXell Therapeutics Unveils Promising Preclinical Data Demonstrating Efficacy of BXT-110, an Autologous iPSC-Derived Neuronal Therapy, in Parkinson’s Disease (PRNewswire) - "The data presented highlights BrainXell Therapeutics' progress in developing a robust, reproducible, and scalable approach for BXT-110, an autologous source of midbrain dopaminergic progenitor (mDAPs) for PD....In vivo studies demonstrated significant graft survival and substantial functional recovery in a 6-OHDA rodent model, with efficacy observed as early as 12 weeks and sustained for up to six months post-transplantation."

Preclinical • Parkinson's Disease